Visión generalGráficoNoticias
Derivados
TraderScreen

Neurocrine Biosciences/  US64125C1099  /

IEX
12/11/2024  16:46:53 Diferencia -0.13 Volumen Bid- Ask- Máximo del día Price Change Band
127.09USD -0.10% 7,905
Volumen de negocios: 1.01 millones		 -Volumen de oferta: - -Tamaño/ Volumen/ Formato de Ask: - 128.23 126.21
GlobeNewswire 02/09 Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Par...
GlobeNewswire 29/08 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 29/08 Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences
GlobeNewswire 28/08 Nxera Pharma Notes Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire 09/08 Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2...
GlobeNewswire 08/08 Xenon Reports Q2 2024 Financial Results and Business Update
GlobeNewswire 07/08 Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company...
GlobeNewswire 06/08 Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
GlobeNewswire 30/07 Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast
GlobeNewswire 23/07 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 09/07 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 13/06 Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
GlobeNewswire 13/06 Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
GlobeNewswire 16/05 Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 f...
GlobeNewswire 13/05 Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 09/05 Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 09/05 Nxera Pharma’s partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of...
GlobeNewswire 09/05 Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2024
GlobeNewswire 08/05 Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene The...
GlobeNewswire 06/05 Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
GlobeNewswire 22/04 Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Th...
GlobeNewswire 16/04 Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel C...
GlobeNewswire 16/04 Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration ...
GlobeNewswire 16/04 Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568
GlobeNewswire 26/03 Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)